Core Viewpoint - The company plans to utilize part of its idle raised funds for cash management, specifically aiming to invest up to 2.1 billion yuan in safe and liquid principal-protected products [1] Group 1: Cash Management Plan - The company will hold its 11th meeting of the 4th Board of Directors on November 21, 2025, to approve the cash management proposal [1] - The proposed investment includes various financial products such as agreed deposits, structured deposits, time deposits, notice deposits, and large certificates of deposit [1] - The approved amount for cash management is valid for 12 months from the date of board approval and can be rolled over within the limit [1] Group 2: Impact on Operations - The company assures that this cash management initiative will not affect the progress of the investment projects funded by the raised capital or its normal production and operations [1] - The income generated from this cash management will be prioritized for supplementing any shortfall in investment projects and for replenishing working capital, with returns directed back to the designated raised funds account as per regulations [1]
禾元生物：拟使用不超21.00亿元闲置募集资金进行现金管理